MiniMed Group, Inc. (MMED)
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-09-04
$23.29-2.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · MMED
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -10.4% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 0 industry peers · Company calendar date is not available
MMED — General Counsel transition
Dated 2026-08-05
General Counsel — Courtney Nelson Wills: The Senior Vice President, General Counsel, and Corporate Secretary is resigning for personal reasons with a planned transition period, representing a genuine loss of a senior officer but not a sudden or negative shock.
Why it matters: Updates on the MiniMed Flex pump will show if the company is moving forward after FDA clearance.
Supportive ifA press release or announcement about the MiniMed Flex insulin pump launch.
Worry ifNo news or delays about the MiniMed Flex insulin pump launch.
Why it matters: Strong sales growth from the MiniMed Flex pump shows its market acceptance. This can drive overall revenue and market share.
Supportive ifU.S. sales of MiniMed Flex pump grow over 20% year over year.
Worry ifU.S. sales of MiniMed Flex pump grow less than 10% year over year.
Why it matters: Management raised its organic revenue growth guidance to about 10.5%. This shows strong business momentum.
Supportive ifOrganic revenue growth reported above 10.5% for Q2 FY27.
Worry ifOrganic revenue growth reported below 10% for Q2 FY27.
Why it matters: FDA approval for MiniMed Fit may increase product options and boost future sales.
Supportive ifFDA grants approval for MiniMed Fit patch pump.
Worry ifFDA delays approval for the MiniMed Fit patch pump longer than expected.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$229 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $564 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,159 loss on $10,000 · 41.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Finishing enrollment in the Vivera trial is important. It helps with future product launches and market growth.
Supportive ifThey said they finished enrolling people in the Vivera trial.
Worry ifThere is a delay in finishing enrollment for the Vivera pivotal trial.